Acquisition of Sanger Sequencing Services

The Food and Drug Administration is forecasting the future acquisition of Sanger sequencing services under NAICS code 518210, with the opportunity posted on May 25, 2026. This procurement is intended to support the agency’s scientific and regulatory functions through high-accuracy DNA sequencing capabilities, though specific technical requirements and scope details are not yet finalized. The place of performance and set-aside status are not specified, indicating the solicitation is still in the planning phase and may be open to various contractor types. The point of contact for program inquiries is the CVM Acquisition Liaison, reachable at cvmacquisitions@fda.hhs.gov, while the contracting officer position remains to be determined. This forecast serves as a preparatory notice to industry stakeholders, allowing potential vendors to prepare proposals and understand upcoming procurement timelines. No formal solicitation number has been assigned, and the official request for proposals will follow at a later date through the OSDBU portal linked in the posting.